Business Context and Reporting Period
This Form 8-K was filed by BioRestorative Therapies, Inc. on February 9, 2015, reporting events occurring on that date and a press release issued on February 17, 2015. The filing primarily addresses the appointment of a new executive officer and the terms of his employment agreement.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to the compensation package for the newly appointed executive:
- Base Salary: $240,000 annually for the initial three months, increasing to $300,000 annually thereafter.
- Performance Bonus: Up to 30% of annual salary based on established goals.
- Severance: Six months of salary under certain circumstances.
- Equity Grant: Option to purchase 500,000 shares of common stock at an exercise price of $0.46 per share.
Material Changes
The material change reported is the appointment of Edward L. Field as President of the Company's brtxDISC Division, effective February 9, 2015. Mr. Field brings prior experience as Chief Operating Officer of Cytomedix, Inc. (now Nuo Therapeutics, Inc.) and Aldagen, Inc.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or management commentary regarding future performance. The document explicitly states that the information furnished is not intended to constitute a determination that the information is material or complete, nor should it be considered before making an investment decision. No specific risks or contingencies are detailed beyond the standard employment terms.
Investor Verification Checklist
- Verify the vesting schedule of the 500,000 stock options granted to Mr. Field (166,667 shares annually over three years).
- Confirm the specific performance goals required to trigger the 30% bonus.
- Review the full text of the Employment Agreement for additional restrictive covenants or termination clauses.
- Check subsequent filings for any updates on the brtxDISC Division's progress under new leadership.